Clinical Trial Update: Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial in invasive triple-negative breast cancer evaluating stereotactic radiotherapy with a PD-1 monoclonal antibody and chemotherapy; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• PD-1 monoclonal antibody

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Breast Cancer Invasive | Phase 2 | Status: NOT_YET_RECRUITING